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Abstract 
Purpose: Interstitial Lung Diseases (ILD) are characterized by inflammation and fibrosis. It de-
scribed the role of hyaluronic acid (HA) as an immune-regulator. It is not known if HA contri- 
butes to the recruitment of inflammatory cells associated with ILD. If this hypothesis was correct, 
then concentrations of HA in bronchoalveolar lavage (BAL) should correlate with the severity of 
ILD. Methods: We collected BAL from 22 ILD patients and 15 control subjects. We determined HA 
and cytokine levels by ELISA. In vitro chemotaxis assays were performed by using a transwell sys- 
tem. Results: We found that ILD patients showed a significant increase in HA, IL-6 levels and the 
amount of cells in BAL compared to control subjects. We detected a significant positive correlation 
between HA and IL-6 levels (r = 0.53 and p < 0.001) and an inverse relationship between HA levels 
and diffusion capacity (r = −0.59, p < 0.01). In vitro, HA induced migration of macrophages and 
monocytes through a CD44-dependent process. BAL from patients with ILD stimulated macro- 
phage migration and this was abrogated by hyaluronidase. Conclusions: Our results support the 
hypothesis that HA contributes to the recruitment of monocytes towards the alveolar space, lead- 
ing to exacerbation of lung inflammation in ILD patients. 
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1. Introduction 
Interstitial lung diseases (ILD) include a heterogeneous group of lung disorders that lead to progressive loss of 
lung function [1]. These illnesses share in common parenchymal inflammation and fibrosis with overproduction 
and deposition of extracellular matrix (ECM) components, distortion of pulmonary architecture, and intra-alveo- 
lar inflammation [2]-[6].  
Hyaluronic acid (HA) is a non-sulfated glycosaminoglycan (GAG) composed by disaccharide D-glucuronic 
acid and N-acetyl-glucosamine. It represents the major component of the ECM and it has been described as an 
immune regulator in human diseases [7]. It has been previously demonstrated that HA levels are significantly 
higher in bronchoalveolar lavage (BAL) from patients with respiratory distress syndrome [8], idiopathic pulmo- 
nary fibrosis [9] and sarcoidosis [10] compared with healthy people. 
HA interacts with different cell surface receptors such as CD44 and Toll-like receptor 2 and 4 (TLR-2 and 
TLR-4) [11] [12]. The interaction of HA with CD44 induces cell motility. Activation of CD44 can also mod- 
ulate proliferation, migration and angiogenesis [13]. Moreover, HA isolated from serum of patients with acute 
lung injury stimulates the production of chemokines by macrophages in TLR-4 and TLR-2 dependent manner 
[14].  
The innate immune system plays a pivotal role in the initiation and progression of lung inflammation. HA has 
been described as a “Damage-Associated Molecular Pattern” (DAMPs), with potential to contribute with sterile 
inflammation associated with ILD pathogenic process [15], however, the role of HA in the inflammatory cell re- 
cruitment in these patients, remains unclear. In the present study we analyzed HA levels in BAL fluid from dif- 
ferent ILD and we evaluated the ability of HA to induce the chemotaxis of alveolar macrophages and circulating 
monocytes. 
2. Materials and Methods 
2.1. Study Design 
The study had a prospective cross-sectional design. The protocol was approved by the ethical committee of Hos- 
pital “María Ferrer” in according with the ethical standards of Helsinski Declaration (1975). Informed consent 
was obtained from all patients and control subjects. 
2.2. Patients and Controls 
2.2.1. Patients with Interstitial Lung Diseases 
Twenty-two adults with ILD, diagnosed according the criteria established by the American Thoracic Society 
(ATS) and the European Respiratory Society (ERS) [16] [17], were included in this study. 
2.2.2. Control Group 
The control group included 15 adults without clinical evidence of ILD, Chronic Obstructive Pulmonary Disease 
(COPD), asthma Bronchoscopy was performed as follow up for post-intubation tracheal stenosis reparative sur- 
gery and BAL samples from middle lobe were collected. The characteristics for ILD patients and control sub-
jects are shown in Table 1. 
2.3. Bronchoalveolar Lavage (BAL) 
Bronchoalveolar lavage was performed as previously described [18]. Sterile saline at room temperature was in- 
stilled through the bronchoscope in aliquots of 20 mL reaching a total volume of 140 mL. It was harvested by 
gentle hand suction applied to each instilled syringe. The BAL was pooled in ice-cold tubes and centrifuged at 
400 g for 10 min at 4˚C. Aliquots of the cell-free supernatant were stored at −70˚C until use. The cell pellet was  
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Table 1. Characteristics of control subjects and ILD patients. NSIP: non-specific interstitial pneumonia. HP: hypersensitivity 
pneumonitis. FVC: forced vital capacity. TLC: total lung capacity. DLCO: diffusing capacity of the lung for carbon monox- 
ide. AV: alveolar volume and ND: non determined. Data are presented as the median and quartiles (25% and 75%).         
Groups N Age (years) Sex 
Pulmonary Function Test 
Status Smoking 
FVC  
(% predicted) 
TLC  
(% predicted) 
DLCO  
(% predicted) 
AV  
(% predicted) 
CONTROL 15 31.0  (24.0 - 58.0) 
Female: 7 
Male: 8 
90.0  
(94.0 - 102.0) ND ND ND 
Never: 13  
Previous: 1  
Current: 1 
NSIP 4 63.0  (54.5 - 70.0) 
Female: 3 
Male: 1 
88.0  
(74.0 - 115.0) 
97.0  
(65.0 - 100.0) 
49.0  
(37.0 - 59.0) 
90.0  
(62.0 - 98.5) 
Never: 4  
Previous: 0  
Current: 0 
SARCOIDOSIS 6 45.0  (36.5 - 50.0) 
Female: 4 
Male: 2 
78.0  
(61.0 - 85.5) 
81.5  
(73.5 - 83.5) 
64.0  
(43.0 - 83.5) 
78.5  
(74.5 - 89.0) 
Never: 1  
Previous: 5  
Current: 0 
HP 12 56.0  (43.0 - 56.5) 
Female: 3 
Male: 9 
54.0  
(44.0 - 74.0) 
59.0  
(47.0 - 78.0) 
42.0  
(34.0 - 47.0) 
57.0  
(48.5 - 68.5) 
Never: 9  
Previous: 3  
Current: 0 
 
washed and BAL cells were resuspended in serum-free RPMI 1640 culture medium. Alveolar macrophages 
were purified by adherence to a 100-mm diameter plastic tissue culture dishes at 37˚C in a humidified atmos- 
phere. After 45 min of incubation, the non-adherent cells were removed and the layer of adherent cells were 
washed twice with 10 ml cold-sterile PBS. The purity of the macrophages was evaluated by measuring the ex- 
pression of MHC class II cell surface receptor (HLA-DR) and CD64 (Fc-gamma receptor 1). 
2.4. Monocytes Purification 
Blood samples were obtained from ILD patients, mononuclear cells were isolated by standard density gradient 
centrifugation on Ficoll-Hypaque. Then, monocytes were purified by using magnetic microbeads conjugated 
with CD14 antibodies following the manufacture’s recommendations. The purity was checked by flow cytome- 
try (>93%). 
2.5. Pulmonary Function Tests 
Pulmonary function tests (PFTs), including spirometry, plethismographic measurement of lung volumes and 
lung diffusing capacity for carbon monoxide (DLCO), were made according to ATS/ERS recommendations. A 
constant volume plethysmograph (Platinum Elite DL, Medical Graphics Corporation) was used for PFTs mea- 
surements. Predicted normal values were those of Crapo [19] [20]. 
2.6. Enzyme Linked Immunosorbent Assay (ELISA) 
Hyaluronic acid levels in BAL and serum samples were measured with a competitive ELISA assay [21]. Briefly, 
96-well microtiter plates were coated with 100 µg/mL HA. Samples or standard HA (Farmatrade, Argentina) 
were incubated in the presence of 1 μg/mL of biotinylated HA-binding protein (bHABP) (Calbiochem, La Jolla, 
CA). The bHABP bound to the wells was determined using an avidin-biotin detection system (Vector labs, Bur- 
lingame, CA). The concentration of HA in the samples were calculated using a standard curve made with re- 
combinant HA. Cytokines (IL-1β, IL-6, IL-8, IFN-γ and TNF-α) in BAL and serum samples were determined by 
ELISA (R&D Systems), following the manufacturer’s recommendations. 
2.7. Flow Cytometry 
To analyse CD64 and HLA-DR expression, 5 × 106 alveolar macrophages were pre-incubated with heat-treated 
IgG (100 μg/ml) to avoid non-specific binding of antibodies to the receptors for the Fc portion of IgG (FcγR). 
Cells were then washed and incubated with a FITC-conjugated mAb directed to CD64 and PE-conjugated mAb 
directed to HLA-DR (BD PharMigen, San Diego, CA). Analysis was performed using a FACS flow cytometer 
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and CellQuest software (BD Biosciences, San Jose, CA). 
2.8. Confocal Microscopy 
BAL cells were placed on poly-L-lysine-coated glass coverslips (12 mm). The coverslips were washed, and 
RPMI 1640 medium was added to further incubate the attached cells for 30 min. Cells were washed, fixed in 3% 
paraformaldehyde, and washed twice with 0.1 mM glycine. Cells were incubated with FITC-conjugated mAb 
directed to HLA-DR or CD64, washed and incubated with propidium iodide for nuclei staining. Coverslips were 
mounted on glass slides. Immunofluorescence images were acquired with a FluoView FV1000 confocal micro- 
scope (Olympus, Tokio, Japan) using a Plapon 60, 1.42 NA oil immersion objective and images were analyzed 
using the Olympus FV10-ASW software [22]. 
2.9. Chemotaxis Assays 
BAL macrophages and monocytes isolated from ILD patients were used in chemotaxis assays. Migration was 
measured using a 24-transwell plate (8 µm pore size, BD FalconTM, USA) [23]. Briefly, cells (3 × 105 cells/ml) 
were added to the upper compartment. Serum-free RPMI medium (diluent), HA (0.25 - 0.45 × 106 Da Contipro 
Group-Farmatrade, Argentine) or BAL from ILD patients, pre-treated, or not, with hyaluronidase for 30 min at 
37˚C (5 U/mL, from bovine testes, Sigma-Aldrich, USA), was added to the lower compartment. After 90 min of 
incubation in 5% CO2 at 37˚C, filters were removed. Cells on the upper side of the membrane were scraped; 
cells attached to the lower side of the membrane were fixed in 2% formaldehyde, stained with 10% DAPI and 
counted in a fluorescence microscope (OLYMPUS BX51, Olympus Corporation). In addition, migrating cells 
from the lower compartment were collected and counted by flow cytometry as the number of cells acquired in a 
minute under a defined flow rate. The migration index was calculated by determining the ratio of migrated cells 
towards HA or BAL versus control medium, taking the spontaneous migration in control wells as 100%. To 
evaluate the capacity of anti-human CD44 monoclonal antibodies (clonKM81) to inhibit HA-mediated migra- 
tion, alveolar macrophages were incubated with the mAbKM81 (20 µg/ml) at 4˚C for 30 min before the start of 
the migration assay. Isotype controls were also included in the experiments. To evaluate random migration, che- 
mokinesis controls were performed by adding HA to both, the upper and lower compartment of the chamber. 
2.10. Statistical Analysis 
Differences between the groups were evaluated by the non-parametric Kruskall Wallis and Dunn’s Multiple 
comparison tests or by one way analysis of variance (ANOVA) and Bonferroni’s multiple comparison test. To 
evaluate the degree of association between HA, cytokine levels and lung function parameters we used a linear 
regression test. Analysis was performed using Prism 4 software (Graph Pad, La Jolla, CA) and Statistixs (USA). 
3. Results 
3.1. Increase in Concentrations of Hyaluronic Acid in Bronchoalveolar Lavage from  
Interstitial Lung Disease Patients Respect to Healthy Subjects 
We found a significant increase in the concentrations of HA in BAL from ILD patients compared with controls: 
non-specific interstitial pneumonia: NSIP: 2057.0 ± 419.9 ng/mL (p < 0.01); hypersensitivity pneumonitis: HP: 
1975.0 ± 199.3 ng/mL (p < 0.001) and sarcoidosis: 1839.0 ± 147.9 ng/mL (p < 0.01) vs controls: 623.5 ± 48.1 
ng/mL (Figure 1(a)). We also measured serum concentrations of HA and found no differences between ILD pa- 
tients and controls: NSIP: 230.0 ± 22.0 ng/mL, HP: 242.0 ± 50.5 ng/mL, sarcoidosis: 270.2 ± 49.0 ng/mL vs 
controls: 210.8 ± 22.1 ng/mL. 
3.2. Increase of Cell Count in Bronchoalveolar Lavage from Interstitial Lung Disease  
Patients Respect to Healthy Subjects 
As shown in Figure 1(b), BAL from ILD patients contained higher number of cells compared with controls: 
NSIP: (0.50 ± 0.07) × 106 cell/mL (p < 0.05); HP: (0.73 ± 0.13) × 106 cells/mL (p < 0.01) and sarcoidosis: (0.82 
± 0.28) × 106 cell/mL (p < 0.05) vs controls = (0.19 ± 0.03) × 106 cell/mL (n = 15). 
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3.3. Concentrations of Cytokines from Interstitial Lung Disease Patients Compared with  
Control Subjects 
We measured the inflammatory cytokines IL-1β, IL-6, IL-8, IFN-γ and TNF-α in BAL samples. There were no 
differences between IFN-γ, TNF-α, IL-1β and IL-8 concentrations in BAL from ILD patients compared with 
control subjects (Figures 2(a)-(d)). ILD patients showed higher levels of IL-6 in BAL, compared with controls: 
NSIP: 359.2 ± 88.4 pg/mL (p < 0.001), HP: 150.4 ± 36.97 pg/mL (p < 0.05), sarcoidosis: 248.5 ± 71.4 pg/mL (p 
< 0.01), respect to controls: 13.47 ± 2.6 pg/mL (Figure 2(e)), however in serum we didn’t find significant dif-  
 
 
Figure 1. Increased levels of HA and cell counts in BAL from ILD patients compared with control subjects. HA levels (a) 
and cell counts (b) were quantified in BAL from NSIP (n = 4), HP (n = 12), Sarcoidosis (n = 6) patients, and control subjects 
(n = 15). *p < 0.05, **p < 0.01, and ***p < 0.001 vs control subjects.                                                
 
 
Figure 2. Concentrations of cytokines in BAL samples from ILD patients. The levels of IFN-γ (a), TNF-α 
(b), IL1-β (c), IL-8 (d), and IL-6 (e) were analyzed by ELISA. (f) Linear regression between the concentra- 
tions of IL-6 and HA in BAL samples from ILD patients. Spearman r = 0.53 and p < 0.001. *p<0.05, **p < 
0.01 and ***p < 0.001.                                                                        
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ferences (data not shown). Interestingly, a positive correlation was found in the BAL of ILD patients between 
the levels of HA and IL-6 (Figure 2(f)) (Spearman r = 0.53 and p < 0.001). 
3.4. Relationship between Hyaluronic Acid Levels in Bronchoalveolar Lavage and  
Pulmonary Function Tests 
We next analyzed the relationship between the concentrations of HA in BAL and the different pulmonary func- 
tion tests performed in ILD patients (see Table 1). These studies revealed an inverse correlation between BAL 
HA levels and the DLCO/VA ratio (Spearman r: −0.59, p < 0.01; Figure 3). However, we didn’t find similar 
relationship between the rest of parameters evaluated (TLC or FVC) and HA concentrations. 
3.5. Hyaluronic Acid Induces the Chemotaxis of Alveolar Macrophages and Peripheral  
Monocytes 
In a first set of experiments, we characterized BAL adherent cells recovered from ILD patients by using mAb 
directed to HLA-DR and CD64. Figure 4 shows that, as expected, adherent cells were mostly positive for the 
expression of HLA-DR and CD64, evaluated by both flow cytometry (Figure 4(a)) and confocal microscopy 
(Figure 4(b)). Migration assays were performed by using HA as chemoattractant. Results in Figure 5(a) indi-
cated that HA stimulated macrophage migration in doses depend manner. Moreover, Figure 5(b) shows that 
pre-treatment of macrophages with antibodies directed to CD44 completely prevented the ability of HA to sti-
mulate macrophage migration while isotype controls did not exert any effect. Moreover, the simultaneous addi-
tion of HA to both the upper and the lower wells of the transwell plate did not stimulate the migration of ma-
crophages, suggesting that HA stimulates the chemotaxis, but not the chemokinesis of macrophages. We also 
observed that a pool of BAL from ILD patients, containing a concentration of HA of 2645 ng/ml stimulated the 
migration of macrophages. Of note, this response was completely prevented by the pre-treatment of BAL with 
hyaluronidase (Figure 5(d)), thus suggesting a major role for HA in the chemotactic response induced by BAL. 
Moreover, we showed similar results when we performed the migration assay using monocytes purified from 
peripheral blood (Figure 5(c) and Figure 5(e)). 
4. Discussion 
In this work we analyzed the role of HA in the migration of inflammatory cells. Our results suggest that AH 
could contribute to the recruitment of macrophages and monocytes through a CD44-dependent process leading 
to exacerbation of lung inflammation in ILD patients. As it has been previously demonstrated, the tissue micro-
environment plays a critical role in regulation of inflammation and ECM degradation products might contribute 
actively in the inflammatory process [24]. Endogenous ligands of TLR are released at the site of tissue injury, 
and can activate the innate immune system prompting “danger signals” [25] [26]; however the mechanisms un-
derlying the pathogenesis of ILD are poorly understood. In the present study we analyzed whether HA might be 
 
 
Figure 3. Relationship between pulmonary function 
tests and levels of HA in BAL from ILD patients. Li- 
near regression between DLCO/VA ratio vs levels of 
HA in BAL samples; Spearman r = −0.59, p < 0.01.    
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Figure 4. Characterization of adherent cells purified from ILD patients. The expression of HLA-DR and CD64 
was analyzed by flow cytometry (a) and confocal microscopy (b). In (a), histograms and a dot-plot from a repre- 
sentative experiment is shown. In (b), cells were labeled with antibodies directed to HLA-DR (green) or CD64 
(green), and nuclei staining was performed with propidium iodide (red). Bar: 10 µm. Graphs are representative of 
five independent experiment.                                                                      
 
involved.  
We found that patients with ILD showed a significant increase in HA and IL-6 levels in BAL compared with 
control subjects. In accordance with our results, other reports have previously shown increased levels of HA in 
patients with farmer’s lung-HP [27] [28], sarcoidosis [10], asbestos-exposed individuals [29] and patients with 
idiopathic pulmonary fibrosis [30]. Our results raise the question about a possible role for HA in the pathogene- 
sis of ILD. In fact, we observed a positive correlation between HA and local inflammation determined by IL-6 
level and an inverse correlation between levels of HA in BAL samples from ILD patients and DLCO/VA ratio.  
Accumulation of HA has shown to be associated to progressive tissue fibrosis [9] and its most important cell 
surface receptor CD44, was shown to be involved in the HA-induced leukocyte infiltration in a murine model of 
arthritis [31]. Moreover, in a recent report, Li and coworkers [32] have reported that severe lung fibrosis re- 
quires an invasive fibroblast phenotype regulated by HA and CD44. Thus, these observations suggest that HA 
might contribute to the pathogenesis of ILD by stimulating both the local recruitment of inflammatory cells and 
the profibrotic activity of fibroblasts. In line with these results, we found that HA, participates in the recruitment 
of monocytes in a CD44-dependent manner in patients with ILDs. 
Though we analyzed a small number of patients we think that HA could play an important role in the recruit- 
ment of monocytes towards the alveolar space, leading to exacerbation of lung inflammation in patients with 
ILD. These findings suggest a novel potential approach to the treatment and/or prevention of ILD. 
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Figure 5. Chemotaxis of BAL macrophages or monocytes purified from peripheral blood induced by HA. In 
all cases, BAL macrophages were isolated from ILD patients. a) Migration of alveolar macrophages in re- 
sponse to different concentrations of HA. Results are the mean ± SEM (n = 10). (b) Macrophages (c) or mo- 
nocytes were pre-treated with the anti-CD44 IgGmAb KM81 (20 µg/ml) for 30 min at 4˚C before the addi- 
tion of HA (2.5 μg/ml). The chemokinesis control was performed by adding HA (20 µg/ml) to both, the up- 
per and the lower compartment of the chamber. Migration towards BAL using macrophages (d) or mono- 
cytes (e) were performed. A pool of BAL harvested from ILD patients containing a concentration of HA of 
2245 ng/ml, were pre-treated, or not, with hyaluronidase (5 U/ml) for 30 min at 37˚C. In all cases, the results 
are expressed as the migration index: MI (%) = (Number of cells that migrated towards HA or BAL/Number 
of cells that migrated towards RPMI) × 100 (n = 5 - 10). *p < 0.05, **p < 0.01 and ***p < 0.001.              
Conflict of Interest Statement 
Authors declare that no conflict of interest exists in the development of this work. This work was supported by 
grants from University of Buenos Aires (UBACYT-B021) and CONICET (PIP-0199). 
Acknowledgements 
We are especially grateful to Dr David D. Gutterman (Medical College of Wisconsin, Milwaukee); Dr. Henri 
G. Ernst et al. 
 
 35 
Colt (University of California, Irvine) and Eric Edell (Mayo Clinic) by reading and correcting the manuscript 
with such dedication. We also thank Dr. Pauline Johnson (University of British Columbia, Vancouver, Canada) 
for providing the blocking anti-CD44 Mab (KM81). 
References 
[1] King Jr., T.E. (2005) Clinical Advances in the Diagnosis and Therapy of the Interstitial Lung Diseases. American Jour- 
nal of Respiratory and Critical Care Medicine, 172, 268-279. http://dx.doi.org/10.1164/rccm.200503-483OE 
[2] Kim, R. and Meyer, K.C. (2008) Therapies for Interstitial Lung Disease: Past, Present and Future. Therapeutic Advanc- 
es in Respiratory Disease, 2, 319-338. http://dx.doi.org/10.1177/1753465808096948 
[3] Nathan, S.D., Shlobin, O.A., Weir, N., Ahmad, S., Kaldjob, J.M., Battle, E., Sheridan, M.J. and du Bois, R.M. (2011) 
Long-Term Course and Prognosis of Idiopathic Pulmonary Fibrosis in the New Millennium. Chest, 141, 221-229.  
http://dx.doi.org/10.1378/chest.10-2572 
[4] Selman, M., King, T.E., Pardo, A., American Thoracic Society, European Respiratory Society and American College 
of Chest Physicians (2001) Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis 
and Implications for Therapy. Annals of Internal Medicine, 134, 136-151.  
http://dx.doi.org/10.7326/0003-4819-134-2-200101160-00015 
[5] Strieter, R.M. (2005) Pathogenesis and Natural History of Usual Interstitial Pneumonia: The Whole Story or the Last 
Chapter of a Long Novel. Chest, 128, 526S-532S. http://dx.doi.org/10.1378/chest.128.5_suppl_1.526S 
[6] Vasakova, M., Sterclova, M., Kolesar, L., Slavcev, A., Pohunek, P., Sulc, J., Skibova, J. and Striz, I. (2009) Bronchoal- 
veolar Lavage Fluid Cellular Characteristics, Functional Parameters and Cytokine and Chemokine Levels in Interstitial 
Lung Diseases. Scandinavian Journal of Immunology, 69, 268-274.  
http://dx.doi.org/10.1111/j.1365-3083.2008.02222.x 
[7] Jiang, D., Liang, J. and Noble, P.W. (2011) Hyaluronan as an Immune Regulator in Human Diseases. Physiological 
Reviews, 91, 221-264. http://dx.doi.org/10.1152/physrev.00052.2009 
[8] Hällgren, R., Samuelsson, T., Laurent, T.C. and Modig, J. (1989) Accumulation of Hyaluronan (Hyaluronic Acid) in 
the Lung in Adult Respiratory Distress Syndrome. The American Review of Respiratory Disease, 139, 682-687.  
http://dx.doi.org/10.1164/ajrccm/139.3.682 
[9] Bjermer, L., Lundgren, R. and Hällgren, R. (1989) Hyaluronan and Type III Procollagen Peptide Concentrations in 
Bronchoalveolar Lavage Fluid in Idiopathic Pulmonary Fibrosis. Thorax, 44, 126-131.  
http://dx.doi.org/10.1136/thx.44.2.126 
[10] Bjermer, L., Eklund, A. and Blaschke, E. (1991) Bronchoalveolar Lavage Fibronectin in Patients with Sarcoidosis: Cor- 
relation to Hyaluronan and Disease Activity. European Respiratory Journal, 4, 965-971. 
[11] Noble, P.W. and Jiang, D. (2006) Matrix Regulation of Lung Injury, Inflammation, and Repair: The Role of Innate Im- 
munity. Proceedings of the American Thoracic Society, 3, 401-404. http://dx.doi.org/10.1513/pats.200604-097AW 
[12] Taylor, K.R., Trowbridge, J.M., Rudisill, J.A., Termeer, C.C., Simon, J.C. and Gallo R.L. (2004) Hyaluronan Frag- 
ments Stimulate Endothelial Recognition of Injury through TLR4. The Journal of Biological Chemistry, 279, 17079- 
17084. http://dx.doi.org/10.1074/jbc.M310859200 
[13] Lesley, J. and Hyman Rand Kincade, P.W. (1993) CD44 and Its Interaction with Extracellular Matrix. Advanced Im-
munology, 54, 271-335. http://dx.doi.org/10.1016/S0065-2776(08)60537-4 
[14] Jiang, D., Liang, J., Fan, J., Yu, S., Chen, S., Luo, Y., Prestwich, G.D., et al. (2005) Regulation of Lung Injury and Re- 
pair by Toll-Like Receptors and Hyaluronan. Nature Medicine, 11, 1173-1179. http://dx.doi.org/10.1038/nm1315 
[15] Kuipers, M.T., van der Poll, T., Schultz, M.J. and Wieland, C.W. (2011) Bench-to-Bedside Review: Damage-Associa- 
ted Molecular Patterns in the Onset of Ventilator-Induced Lung Injury. Critical Care, 15, 235-246.  
http://dx.doi.org/10.1186/cc10437 
[16] American Thoracic Society, European Respiratory Society (2002) American Thoracic Society/European Respiratory 
Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. American 
Journal of Respiratory and Critical Care Medicine, 165, 277-304. http://dx.doi.org/10.1164/ajrccm.165.2.ats01 
[17] Travis, W.D., Costabel, U., Hansell, D.M., King Jr., T.E., Lynch, D.A. and Nicholson, A.G. (2013) An Official Amer-
ican Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classifi-
cation of the Idiopathic Interstitial Pneumonias. American Journal of Respiratory and Critical Care Medicine, 188, 
733-748. http://dx.doi.org/10.1164/rccm.201308-1483ST 
[18] Meyer, K.C., Raghu, G., Baughman, R.P., Brown, K.K., Costabel, U., du Bois, R.M., et al. (2012) An Official Ameri-
can Thoracic Society Clinical Practice Guideline: The Clinical Utility of Bronchoalveolar Lavage Cellular Analysis in 
Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 185, 1004-1014.  
G. Ernst et al. 
 
 36 
http://dx.doi.org/10.1164/rccm.201202-0320ST 
[19] Miller, M.R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A. and Crapo, R. (2005) Standardisation of 
Spirometry. European Respiratory Journal, 26,319-338. http://dx.doi.org/10.1183/09031936.05.00034805 
[20] Macintyre, N., Crapo, R.O., Viegi, G., Johnson, D.C., van der Grinten, C.P., Brusasco, V. and Burgos, F. (2005) Stan-
dardisation of the Single-Breath Determination of Carbon Monoxide Uptake in the Lung. European Respiratory Jour-
nal, 26, 720-735. http://dx.doi.org/10.1183/09031936.05.00034905 
[21] Cordo Russo, R.I., Ernst, G., Lompardía, S., Blanco, G., Álvarez, É., Garcia, M.G. and Hajos, S. (2012) Increased 
Hyaluronan Levels and Decreased Dendritic Cell Activation Are Associated with Tumor Invasion in Murine Lym-
phoma Cell Lines. Immunobiology, 217, 842-850. http://dx.doi.org/10.1016/j.imbio.2011.12.006 
[22] Jancic, C.C., Cabrini, M., Gabelloni, M.L., Rodríguez, Rodrigues, C., Salamone, G., Trevani, A.S. and Geffner, J. 
(2012) Low Extracellular pH Stimulates the Production of IL-1β by Human Monocytes. Cytokine, 57, 258-268.  
http://dx.doi.org/10.1016/j.cyto.2011.11.013 
[23] Ernst, G., Lompardía, S., Cordo Russo, R., Gentilini, V., Venturiello, S., Galíndez, F., Grynblat, P. and Hajos, S.E. 
(2012) Corticosteroid Administration Reduces the Concentration of Hyaluronan in Bronchoalveolar Lavage in a Mu-
rine Model of Eosinophilic Airway Inflammation. Inflammation Research, 61, 1309-1317.  
http://dx.doi.org/10.1007/s00011-012-0530-y 
[24] Collins, S.L., Black, K.E., Yee, C.-L., Ahn, Y.-H., Cole, P.A., Powell, J.D. and Horton, M.R. (2011) Hyaluronan Frag- 
ments Promote Inflammation by Down-Regulating the Anti-Inflammatory A2a Receptor. American Journal of Respi-
ratory Cell and Molecular Biology, 45, 675-683. http://dx.doi.org/10.1165/rcmb.2010-0387OC 
[25] Scheibner, K.A., Lutz, M.A., Boodoo, S., Fenton, M.J., Powell, J.D. and Horton, M.R. (2006) Hyaluronan Fragments 
Act as an Endogenous Danger Signal by Engaging TLR2. The Journal of Immunology, 177, 1272-1281. 
[26] Powell, J.D. and Horton, M.R. (2005) Threat Matrix: Low-Molecular-Weight Hyaluronan (HA) as a Danger Signal. 
Immunologic Research, 31, 207-218. http://dx.doi.org/10.1385/IR:31:3:207 
[27] Bjermer, L., Engström-Laurent, A., Lundgren, R., Rosenhall, L. and Hällgren, R. (1987) Hyaluronate and Type III 
Procollagen Peptide Concentrations in Bronchoalveolar Lavage Fluid as Markers of Disease Activity in Farmer’s Lung. 
British Medical Journal (Clinical Research Ed.), 295, 803-806. http://dx.doi.org/10.1136/bmj.295.6602.803 
[28] Cormier, Y,. Laviolette, M., Cantin, A., Tremblay, G.M. and Bégin, R. (1993) Fibrogenic Activities in Bronchoalveo-
lar Lavage Fluid of Farmer’s Lung. Chest, 104, 1038-1042. http://dx.doi.org/10.1378/chest.104.4.1038 
[29] Cantin, A.M., Larivée, P., Martel, M. and Bégin, R. (1992) Hyaluronan (Hyaluronic Acid) in Lung Lavage of Asbes-
tos-Exposed Humans and Sheep. Lung, 170, 211-220. http://dx.doi.org/10.1007/BF00174118 
[30] Milman, N., Kristensen, M.S. and Bentsen, K. (1995) Hyaluronan and Procollagen Type III Aminoterminal Peptide in 
Serum and Bronchoalveolar Lavage Fluid from Patients with Pulmonary Fibrosis. APMIS, 103, 749-754.  
http://dx.doi.org/10.1111/j.1699-0463.1995.tb01433.x 
[31] Mikecz, K., Brennan, F.R., Kim, J.H. and Glant, T.T. (1995) Anti-CD44 Treatment Abrogates Tissue Oedema and 
Leukocyte Infiltration in Murine Arthritis. Nature Medicine, 1, 558-563. http://dx.doi.org/10.1038/nm0695-558 
[32] Li, Y., Jiang, D., Liang, J., Meltzer, E.B., Gray, A., Miura, R., Wogensen, L., Yamaguchi, Y. and Noble, P.W. (2011) 
Severe Lung Fibrosis Requires an Invasive Fibroblast Phenotype Regulated by Hyaluronan and CD44. The Journal of 
Experimental Medicine, 208, 1459-1471. http://dx.doi.org/10.1084/jem.20102510 
